`
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`_______________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_____________
`
`
`MYLAN TECHNOLOGIES, INC.
`Petitioner
`v.
`
`NOVEN PHARMACEUTICALS, INC.
`Patent Owner.
`
`_______________
`
`Case No. IPR2018-01119
`U.S. Patent No. 9,833,419
`____________________________________________________________
`
`JOINT MOTION TO TERMINATE PROCEEDINGS
`PURSUANT TO 35 U.S.C. § 3171
`
`
`
`1 Identical documents are being filed in IPR2018-00173 and IPR2018-00174.
`
`
`
`U.S. Patent No. 9,833,419
`IPR2018-01119
`
`As authorized in the Patent Trial and Appeal Board’s email dated August 24,
`
`2018, and pursuant to 35 U.S.C. § 317(a) and 37 C.F.R. §§ 42.72 and 42.74, Patent
`
`Owner and Petitioner jointly and respectfully request that the inter partes reviews
`
`of U.S. Patent No. 9,724,310 (“the ’310 Patent”) (IPR2018-00173), U.S. Patent
`
`No. 9,730,900 (“the ’900 Patent”) (IPR2018-00174), and U.S. Patent No.
`
`9,833,419 (“the ’419 Patent”) (IPR2018-0119) be terminated. In accordance with
`
`the Board’s email, this motion includes (1) a brief explanation why termination is
`
`appropriate and (2) identifies all parties in pending district court litigation
`
`involving the patents and the current status of each such litigation. There are no
`
`other pending inter partes review proceedings involving the patents.
`
`I.
`
`Statement of Relief Requested
`
`Pursuant to 35 U.S.C. § 317, 37 C.F.R. § 42.72, and 37 C.F.R. § 42.74, and
`
`pursuant to the authorization to file this motion provided by the Board’s email to
`
`the parties on August 24, 2018, Petitioner Mylan Technologies, Inc. and Patent
`
`Owner Noven Pharmaceuticals, Inc. (collectively, the “Parties”) jointly request the
`
`termination of the inter partes reviews of the ’310 Patent (IPR2018-00173), the
`
`’900 Patent (IPR2018-00174), and the ’419 Patent (IPR2018-0119) in their entirety
`
`as a result of settlement between the Parties.
`
`The Parties have settled their dispute and executed a binding term sheet to
`
`terminate these inter partes reviews. The Parties’ binding term sheet has been
`
`1
`
`
`
`U.S. Patent No. 9,833,419
`IPR2018-01119
`
`made in writing, and a true and correct copy is being filed concurrently herewith as
`
`Exhibit 2025 (“Binding Term Sheet”). The Parties are also filing concurrently
`
`herewith a joint request to treat the Binding Term Sheet as business confidential
`
`information and keep it separate from the files of the inter partes reviews and the
`
`involved patents pursuant to 35 U.S.C. § 317(b) and 37 C.F.R. § 42.74(b) and (c).
`
`The Binding Term Sheet reflects all essential terms of a settlement agreement
`
`between the Parties. At the Board’s request, the Parties will provide the Board
`
`with a copy of the settlement agreement once it has been duly executed.
`
`II.
`
`Statement of Facts
`A.
`IPR2018-00173 and IPR2018-00174
`Petitioner filed petitions requesting inter partes reviews of the ’310 Patent
`
`and the ’900 Patent on December 4, 2017. Patent Owner filed preliminary
`
`responses on March 13, 2018, and on June 12, 2018, the Board denied institution
`
`in both IPR2018-00173 and IPR2018-00174. Thereafter, Petitioner filed requests
`
`for rehearing on July 12, 2018, and Patent Owner filed oppositions to the requests
`
`for rehearing on July 20, 2018. The Board has not yet issued decisions on the
`
`requests for rehearing in IPR2018-00173 and IPR2018-00174.
`
`IPR2018-01119
`
`B.
`Petitioner filed a petition requesting inter partes review of the ’419 Patent (a
`
`related continuation of the ’310 and ’900 Patents) on May 18, 2018. Patent Owner
`
`2
`
`
`
`U.S. Patent No. 9,833,419
`IPR2018-01119
`
`filed a preliminary response on August 22, 2018. The Board has not yet issued an
`
`institution decision in IPR2018-01119.
`
`III. Argument
`35 U.S.C. § 317(a) provides: “An inter partes review instituted under this
`
`chapter shall be terminated with respect to any petitioner upon the joint request of
`
`the petitioner and the patent owner, unless the Office has decided the merits of the
`
`proceeding before the request for termination is filed.” 35 U.S.C. § 317(a).
`
`Similarly, 37 C.F.R. § 42.72 provides that “[t]he Board may terminate a trial
`
`without rendering a final written decision, where appropriate, including where the
`
`trial is consolidated with another proceeding or pursuant to a joint request under 35
`
`U.S.C. 317(a).” The Trial Practice Guide additionally counsels that “[t]here are
`
`strong public policy reasons to favor settlement between the parties to proceeding”
`
`and that the Board “expects that a proceeding will terminate after the filing of a
`
`settlement agreement, unless the Board has already decided the merits of the
`
`proceeding. 35 U.S.C. 317(a), as amended, and 35 U.S.C. 327.” Office Patent
`
`Trial Practice Guide, 77 Fed. Reg. 48,756, 48,768 (Aug. 14, 2012).
`
`A. Explanation Why Termination Is Appropriate
`In accordance with the Binding Term Sheet, the Parties are seeking to
`
`terminate these inter partes reviews. The other proceedings related to the
`
`challenged patents involving the Parties, i.e., Noven Pharmaceuticals, Inc. v.
`
`3
`
`
`
`U.S. Patent No. 9,833,419
`IPR2018-01119
`
`Mylan Technologies Inc., et al., C.A. No. 1:17-cv-01777-LPS (D. Del.), and
`
`related Federal Circuit Appeal No. 18-2287, have been dismissed. Thus, no
`
`dispute remains between the Parties involving the ’310 Patent, the ’900 Patent, or
`
`the ’419 Patent.
`
`As noted in the Statement of Facts, the Board has not yet issued decisions on
`
`the requests for rehearing in IPR2018-00173 and IPR2018-00174 and has not yet
`
`decided whether to institute in IPR2018-01119. Thus, the Board has not yet
`
`“decided the merits of the proceeding[s] before the request for termination is
`
`filed.” 35 U.S.C. § 317(a); 77 Fed. Reg. at 48,768.
`
`The Parties are unaware of any other matters before the Board that would be
`
`affected by the outcome of these proceedings. There are no other pending inter
`
`partes review proceedings involving the patents.
`
`Further, because the Board has yet to issue a final decision on the merits,
`
`termination of the proceedings would save the Board significant administrative
`
`resources and limit unnecessary and counterproductive costs. Termination also
`
`would further the AIA’s purpose of providing an efficient and less costly
`
`alternative forum for patent disputes and its encouragement for settlement.
`
`Pending District Court Litigation Involving The Patents
`
`B.
`In addition to the litigation dismissed by the Parties, the following district
`
`court proceedings involving the patents are pending:
`
`4
`
`
`
`(1) Noven Pharmaceuticals, Inc. v. Alvogen Pine Brook LLC, et al., C.A.
`
`U.S. Patent No. 9,833,419
`IPR2018-01119
`
`No. 1:17-cv-01429-LPS (D. Del.).
`
`Plaintiff: Noven Pharmaceuticals, Inc.
`
`Defendants: Alvogen Pine Brook LLC; Alvogen, Inc.; 3M Company
`
`Status: In discovery phase; bench trial scheduled for December 2018
`
`(2) Noven Pharmaceuticals, Inc. v. Amneal Pharmaceuticals LLC, C.A. No.
`
`1:18-cv-00699-LPS (D. Del.)
`
`Plaintiff: Noven Pharmaceuticals, Inc.
`
`Defendant / Third Party Plaintiff: Amneal Pharmaceuticals LLC
`
`Third Party Defendant: Hisamitsu Pharmaceutical Co., Inc.
`
`Status: In discovery phase; the court has not yet set a trial date
`
`(3) Noven Pharmaceuticals, Inc. v. Actavis Laboratories UT, Inc., C.A. No.
`
`1:18-cv-00758-LPS (D. Del.).
`
`Plaintiff: Noven Pharmaceuticals, Inc.
`
`Defendant: Actavis Laboratories UT, Inc.
`
`Status: In pleadings phase; the court has not yet set a trial date
`
`
`
`
`
`* * * * *
`
`5
`
`
`
`U.S. Patent No. 9,833,419
`IPR2018-01119
`
`For the foregoing reasons, the Parties respectfully request that the Board
`
`terminate the inter partes reviews of the ’310 Patent (IPR2018-00173), the ’900
`
`Patent (IPR2018-00174), and the ’419 Patent (IPR2018-0119) in their entirety.
`
`
`
`
`
`
`
`
`
`Respectfully submitted,
`
`
`
`/ Courtenay C. Brinckerhoff /
`Courtenay C. Brinckerhoff
`Registration No. 37,288
`
`Jason N. Mock
`Registration No. 69,186
`
`Counsel for Patent Owner
`Foley & Lardner LLP
`
`6
`
`
`
`
`
`
`
`
`
`
`
`Dated: September 5, 2018
`
` /
`
` Steven W. Parmelee /
`
`Steven W. Parmelee
`Registration No. 31,990
`
`Michael T. Rosato
`Registration No. 52,182
`
`
`
`Jad A. Mills
`Registration No. 63,344
`
`Counsel for Petitioner
`Wilson, Sonsini, Goodrich, & Rosati
`
`
`
`
`
`
`
`
`
`
`
`U.S. Patent No. 9,833,419
`IPR2018-01119
`
`CERTIFICATE OF SERVICE
`
`The undersigned hereby certifies that a copy of the foregoing Joint Motion
`
`to Terminate Proceedings Pursuant to 35 U.S.C. § 317 and accompanying
`
`Exhibit 2025 are being served on September 5, 2018, by filing them through the
`
`PTAB E2E System as well as by email directed to the attorneys of record for the
`
`Petitioner at the following addresses:
`
`sparmelee@wsgr.com
`mrosato@wsgr.com
`jmills@wsgr.com
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`By: / Courtenay C. Brinckerhoff /
`Courtenay C. Brinckerhoff
`Registration No. 37,288
`
`Jason N. Mock
`Registration No. 69,186
`
`Counsel for Patent Owner
`Foley & Lardner LLP
`
`
`
`
`
`
`
`
`
`
`
`
`
`